+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Liquid Biopsy Market (2023-2028) Competitive Analysis, Impact of Covid-19, Ansoff Analysis

  • PDF Icon


  • 177 Pages
  • February 2024
  • Region: Global
  • Infogence Global Research
  • ID: 5669429

Companion diagnostics include tests or assays intended to assist healthcare providers in making treatment decisions for patients based on the best response to therapy

The Global Liquid Biopsy Market is estimated to be USD 1.65 Bn in 2023 and is expected to reach USD 4.15 Bn by 2028 growing at a CAGR of 20.28%

Market Dynamics

Market dynamics are forces that impact the prices and behaviors of the stakeholders. These forces create pricing signals which result from the changes in the supply and demand curves for a given product or service. Forces of Market Dynamics may be related to macro-economic and micro-economic factors. There are dynamic market forces other than price, demand, and supply. Human emotions can also drive decisions, influence the market, and create price signals.

As the market dynamics impact the supply and demand curves, decision-makers aim to determine the best way to use various financial tools to stem various strategies for speeding the growth and reducing the risks.

Market Segmentations

  • The Global Liquid Biopsy Market is segmented based on Product, Sample, Type, Technology, Application, Indication, and Geography.
  • By Product, the market is classified into Cell-free DNA, Circulating Tumor Cells, Circulating Tumor DNA, Exosome and Extracellular Vesicles.
  • By Sample, the market is classified into Blood Based and Urine Based.
  • By Type, the market is classified into Assay Kits, Instruments and Services.
  • By Technology, the market is classified into Multi-gene Parallel Analysis using NGS and Single-gene Analysis using PCR Microarrays.
  • By Application, the market is classified into Early Cancer Screening, Recurrence Monitoring, Therapy Selection and Treatment Monitoring.
  • By Indication, the market is classified into Cancer Indication and Non-cancer Indication.
  • By Geography, the market is classified into Americas, Europe, Middle East & Africa, and Asia-Pacific.

Company Profiles

The report provides a detailed analysis of the competitors in the market. It covers the financial performance analysis for the publicly listed companies in the market. The report also offers detailed information on the companies' recent development and competitive scenario. Some of the companies covered in this report are Qiagen N.V., F. Hoffmann-la Roche, Myriad Genetics, Inc., Thermo Fisher Scientific Inc., Guardant Health, Inc., Bio-Rad Laboratories, Illumina, Inc., Exact Sciences, etc.

Countries Studied

  • America (Argentina, Brazil, Canada, Chile, Colombia, Mexico, Peru, United States, Rest of Americas)
  • Europe (Austria, Belgium, Denmark, Finland, France, Germany, Italy, Netherlands, Norway, Poland, Russia, Spain, Sweden, Switzerland, United Kingdom, Rest of Europe)
  • Middle-East and Africa (Egypt, Israel, Qatar, Saudi Arabia, South Africa, United Arab Emirates, Rest of MEA)
  • Asia-Pacific (Australia, Bangladesh, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Sri Lanka, Thailand, Taiwan, Rest of Asia-Pacific)

Competitive Quadrant

The report includes Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.

Ansoff Analysis

  • The report presents a detailed Ansoff matrix analysis for the Global Liquid Biopsy Market. Ansoff Matrix, also known as Product/Market Expansion Grid, is a strategic tool used to design strategies for the growth of the company. The matrix can be used to evaluate approaches in four strategies viz. Market Development, Market Penetration, Product Development and Diversification. The matrix is also used for risk analysis to understand the risk involved with each approach.
  • The publisher analyses the Global Liquid Biopsy Market using the Ansoff Matrix to provide the best approaches a company can take to improve its market position.
  • Based on the SWOT analysis conducted on the industry and industry players, the publisher has devised suitable strategies for market growth.

Why buy this report?

  • The report offers a comprehensive evaluation of the Global Liquid Biopsy Market. The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies.
  • The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel in the industry.
  • The report includes an in-depth market analysis using Porter's 5 forces model and the Ansoff Matrix. In addition, the impact of Covid-19 on the market is also featured in the report.
  • The report also includes the regulatory scenario in the industry, which will help you make a well-informed decision. The report discusses major regulatory bodies and major rules and regulations imposed on this sector across various geographies.
  • The report also contains the competitive analysis using Positioning Quadrants, the Proprietary competitive positioning tool.

Report Highlights:

  • A complete analysis of the market, including parent industry
  • Important market dynamics and trends
  • Market segmentation
  • Historical, current, and projected size of the market based on value and volume
  • Market shares and strategies of key players
  • Recommendations to companies for strengthening their foothold in the market

Table of Contents

1 Report Description
1.1 Study Objectives
1.2 Market Definition
1.3 Currency
1.4 Years Considered
1.5 Language
1.6 Key Stakeholders
2 Research Methodology
2.1 Research Process
2.2 Data Collection and Validation
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Models
2.3 Market Size Estimation
2.3.1 Bottom-Up Approach
2.3.2 Top-Down Approach
2.4 Assumptions of the Study
2.5 Limitations of the Study
3 Executive Summary
3.1 Introduction
3.2 Market Size, Segmentations, and Outlook
4 Market Dynamics
4.1 Drivers
4.1.1 Rising Incidence and Prevalence of Cancer
4.1.2 Increasing Preference for Noninvasive Diagnostic Procedures
4.1.3 Availability of Funding to Expand Cancer Research in the Field of Liquid Biopsy
4.2 Restraints
4.2.1 Low Abundance and Fragile Nature of the Circulating Tumor Cells (CTCs)
4.2.2 The Lower Sensitivity of Certain Liquid Biopsies
4.3 Opportunities
4.3.1 Significant use of Microarrays and Next-generation Sequencing (NGS)
4.3.2 Ongoing Development of Advanced Liquid Biopsy Assays
4.4 Challenges
4.4.1 Unclear Regulatory and Reimbursement Scenario
5 Market Analysis
5.1 Regulatory Scenario
5.2 Porter's Five Forces Analysis
5.3 Impact of COVID-19
5.4 Ansoff Matrix Analysis
5.5 PESTLE Analysis
6 Global Liquid Biopsy Market, By Product
6.1 Introduction
6.2 Cell-free DNA
6.3 Circulating Tumor Cells
6.4 Circulating Tumor DNA
6.5 Exosome
6.6 Extracellular Vesicles
7 Global Liquid Biopsy Market, By Sample
7.1 Introduction
7.2 Blood Based
7.3 Urine Based
8 Global Liquid Biopsy Market, By Type
8.1 Introduction
8.2 Assay Kits
8.3 Instruments
8.4 Services
9 Global Liquid Biopsy Market, By Technology
9.1 Introduction
9.2 Multi-gene Parallel Analysis using NGS
9.3 Single-gene Analysis using PCR Microarrays
10 Global Liquid Biopsy Market, By Application
10.1 Introduction
10.2 Early Cancer Screening
10.3 Recurrence Monitoring
10.4 Therapy Selection
10.5 Treatment Monitoring
11 Global Liquid Biopsy Market, By Indication
11.1 Introduction
11.2 Cancer Indication
11.2.1 Breast Cancer
11.2.2 Colorectal Cancer
11.2.3 Lung Cancer
11.2.4 Melanoma
11.2.5 Prostate Cancer
11.3 Non-cancer Indication
12 Americas’ Liquid Biopsy Market
12.1 Introduction
12.2 Argentina
12.3 Brazil
12.4 Canada
12.5 Chile
12.6 Colombia
12.7 Mexico
12.8 Peru
12.9 United States
12.10 Rest of Americas
13 Europe’s Liquid Biopsy Market
13.1 Introduction
13.2 Austria
13.3 Belgium
13.4 Denmark
13.5 Finland
13.6 France
13.7 Germany
13.8 Italy
13.9 Netherlands
13.10 Norway
13.11 Poland
13.12 Russia
13.13 Spain
13.14 Sweden
13.15 Switzerland
13.16 United Kingdom
13.17 Rest of Europe
14 Middle East and Africa’s Liquid Biopsy Market
14.1 Introduction
14.2 Egypt
14.3 Israel
14.4 Qatar
14.5 Saudi Arabia
14.6 South Africa
14.7 United Arab Emirates
14.8 Rest of MEA
15 APAC’s Liquid Biopsy Market
15.1 Introduction
15.2 Australia
15.3 Bangladesh
15.4 China
15.5 India
15.6 Indonesia
15.7 Japan
15.8 Malaysia
15.9 Philippines
15.10 Singapore
15.11 South Korea
15.12 Sri Lanka
15.13 Thailand
15.14 Taiwan
15.15 Rest of Asia-Pacific
16 Competitive Landscape
16.1 Competitive Quadrant
16.2 Market Share Analysis
16.3 Strategic Initiatives
16.3.1 M&A and Investments
16.3.2 Partnerships and Collaborations
16.3.3 Product Developments and Improvements
17 Company Profiles
17.1 Qiagen N.V.
17.2 F. Hoffmann-la Roche
17.3 Myriad Genetics, Inc.
17.4 Thermo Fisher Scientific Inc.
17.5 Guardant Health, Inc.
17.6 Bio-Rad Laboratories
17.7 Illumina, Inc.
17.8 Exact Sciences
17.9 Sysmex Inostics
17.10 Biocept, Inc.
17.11 Mdx Health
17.12 Neogenomics, Inc.
17.13 Angle Plc
17.14 Epigenomics Ag
17.15 Menarini-Silicon Biosystems
17.16 Vortex Biosciences, Inc.
17.17 Exosome Diagnostics, Inc.
17.18 Medgenome Inc.
17.19 Agena Bioscience, Inc.
17.20 Personal Genome Diagnostics, Inc.
17.21 Freenome Holdings, Inc.
17.22 Strand Life Sciences
17.23 Lunglife AI, Inc.
17.24 Lucene Health, Inc.
17.25 Anpac Bio-Medical Science Co., Ltd.
18 Appendix
18.1 Questionnaire

Companies Mentioned

  • Qiagen N.V.
  • F. Hoffmann-la Roche
  • Myriad Genetics, Inc.
  • Thermo Fisher Scientific Inc.
  • Guardant Health, Inc.
  • Bio-Rad Laboratories
  • Illumina, Inc.
  • Exact Sciences
  • Sysmex Inostics
  • Biocept, Inc.
  • Mdx Health
  • Neogenomics, Inc.
  • Angle Plc
  • Epigenomics Ag
  • Menarini-Silicon Biosystems
  • Vortex Biosciences, Inc.
  • Exosome Diagnostics, Inc.
  • Medgenome Inc.
  • Agena Bioscience, Inc.
  • Personal Genome Diagnostics, Inc.
  • Freenome Holdings, Inc.
  • Strand Life Sciences
  • Lunglife AI, Inc.
  • Lucene Health, Inc.
  • Anpac Bio-Medical Science Co., Ltd.

Table Information